周三，Oppenheimer重申了Corvus Pharmaceuticals (NASDAQ:CRVS)的优于大盘评级，并维持了14.00美元的目标价，这是在该公司宣布其针对特应性皮炎 (AD)的soquelitinib第一阶段研究中期结果令人鼓舞之后。

Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profileData includes complete results from ...

Investing.com -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS)股票最初下跌高达18%，但随后出现显著反转，在公布其用于治疗中度至重度特应性皮炎的soquelitinib的I期试验中期结果后上涨7%。这家临床阶段生物制药公司发布的数据显示了良好的安全性和有效性，表明该药物不仅对这种慢性皮肤病有潜力，对其他免疫疾病也有潜力。

Corvus Pharmaceuticals' stock plummeted ~40% after Phase 1 data for soquelitinib in AD showed mixed results. See why I ...

Corvus Pharmaceuticals develops next-gen ITK inhibitors, with promising Phase 1 results. Read why CRVS stock can thrive in ...

Corvus Pharmaceuticals (NASDAQ:CRVS) lost ~34% in the premarket on Wednesday after the company announced early results from a ...

During the randomized, double-blind, placebo-controlled trial, 12 patients received soquelitinib oral twice per day and 4 patients received placebo for 28 days and were followed up for 30 days. The ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients ...

Corvus Robotics' autonomous drones are revolutionizing warehouse inventory management with precision and efficiency.

U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Tuesday. Heico reported ...

The Bill & Melinda Gates Foundation will invest up to $50 million in Tessera’s in vivo sickle cell therapy. Elsewhere, Cara ...

Nukkleus Inc. NUKK gained 55.1% to $18.42 in pre-market trading. Nukkleus shares jumped 755% on Tuesday after the company ...